Haleon plc (HLN) Stock Price & How to Invest

Haleon plc is one of the world's largest standalone consumer-health companies, created when GSK demerged its consumer division in 2022. It sells everyday over-the-counter products across five categories: Oral Health (Sensodyne, parodontax, Polident), Pain Relief (Advil, Panadol, Voltaren), Respiratory Health (Theraflu, Otrivin), Vitamins, Minerals and Supplements (Centrum, Emergen-C), and Digestive Health and Therapeutic Skin Health (Tums, Fenistil). The company generated roughly 11 billion pounds (about ~$14 billion) of revenue in 2025 and holds leading or top-tier positions in many of its categories, which gives it pricing power and broad global distribution across pharmacy, grocery, and e-commerce channels.

The investment picture centers on Haleon as a defensive compounder. Growth is driven by trusted brands, innovation launches, and expansion in emerging markets, while management has focused on margin expansion, debt reduction, and returning cash through dividends and buybacks. Pfizer, a legacy shareholder from the GSK-Pfizer consumer joint venture, fully exited its stake in 2025, removing a long-standing overhang. The trade-off is that a slow-and-steady category (single-digit organic growth) means the stock is valued as a stable consumer-staples name rather than a high-growth story, so returns depend heavily on execution, currency, and valuation.

Organic growth has run at the low end of category norms (about 3% in 2025), pressured by a weak cold and flu season and soft North American consumer confidence, so a slow-growth profile is a persistent concern. The US pain market has been weak, weighing on Advil despite share gains. Haleon competes against far larger, deeper-pocketed rivals, faces private-label pressure, and carries meaningful debt from its demerger. As a UK-based company reporting in pounds, ADR holders are exposed to currency swings, and regulatory or product-liability issues in over-the-counter categories are an ongoing tail risk.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Haleon plc's investor relations page or your broker.

• Revenue (FY2025): ~£11.0B (~$14B)
• Q1 2026 revenue: ~£2.86B (+2.2% organic)
• Market cap: ~$41B
• Trailing P/E: ~18x
• Forward P/E: ~16-17x
• Dividend yield: ~2-3%

Haleon trades at a valuation broadly in line with large consumer-staples peers, reflecting its defensive, cash-generative profile rather than a growth premium. Management guides to 3-5% organic revenue growth for 2026 (accelerating through the year) and medium-term targets of 4-6% organic revenue growth with high-single-digit adjusted operating profit growth. Figures are approximate and vary with currency and reporting conventions for the ADR.

There are three common ways to get HLN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so HLN sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where HLN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Haleon is a large, cash-generative consumer-health owner of everyday brands whose appeal rests on steady organic growth and margin expansion rather than rapid top-line acceleration.

Whether HLN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HLN a buy?, and where the stock could go from here in the HLN stock forecast.

For income investors, whether HLN pays a dividend and how the payout looks is covered in does HLN pay a dividend?